Neurocrine Biosciences (NBIX) EPS (Basic) (2010 - 2026)

Neurocrine Biosciences has reported EPS (Basic) for 17 years, with the latest figure at $1.97 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Basic) rose 2362.5% year-over-year to $1.97; the trailing twelve-month figure through Mar 2026 stood at $6.71 (up 121.45% YoY), and the FY2025 full-year result was $4.81, up 41.47% from the prior year.
• EPS (Basic) for Q1 2026 stood at $1.97, up from $1.54 in the prior quarter.
• The five-year high for EPS (Basic) was $2.11 in Q3 2025, with the low at -$0.79 in Q1 2023.
• Historically, EPS (Basic) has averaged $0.84 across 5 years, with a median of $0.92 in 2022.
• Annual changes were most pronounced in 2023 — EPS (Basic) slumped 626.67% — and 2026, when it jumped 2362.5%.
• Neurocrine Biosciences' EPS (Basic) stood at $0.92 in 2022, then jumped by 64.13% to $1.51 in 2023, then tumbled by 31.79% to $1.03 in 2024, then soared by 49.51% to $1.54 in 2025, then gained by 27.92% to $1.97 in 2026.
• The last three EPS (Basic) figures came in at $1.97 (Q1 2026), $1.54 (Q4 2025), and $2.11 (Q3 2025), per Business Quant data.